On June 21, 2016, Mayo Clinic Proceedings published an important article on
men’s health and testosterone.
In 2015 the FDA compelled label changes for all testosterone products marketed
in the United States. This label change effectively limited indications
for prescribing testosterone. Physicians and patients have been concerned
and even confused about diagnosing and treating low testosterone.
Sexual Medicine Society of North America convened an expert panel to evaluate the existing evidence on low testosterone.
In particular, the panel focused on low testosterone associated with low
or normal gonadotropin levels. This common clinical scenario accounts
for most men with low testosterone and has been named Adult Onset Hypogonadism
(AOH). After reviewing the evidence, the panel concluded that men who
present with AOH often have other common disease states like diabetes
or metabolic syndrome. The panel notes that men with AOH should be counseled
regarding the benefits and risks of treatment with testosterone.
The panel detailed a rigorous diagnostic process to ensure that men with
AOH are accurately identified. In addition, the panel noted that men who
are treated with testosterone must be followed regularly for indications
of benefit and for adverse events.
Several authors discuss
Adult Onset Hypogonadism and how it differs from classic diagnoses of Primary and Secondary Hypogonadism.
Irwin Goldstein, MD, medical director of the
sexual medicine program at Alvarado Hospital was among several national experts who contributed
to the review and recommendations, published today in
Mayo Clinic Proceedings.
To interview Dr. Goldstein, editor-in-chief of
Sexual Medicine Reviews,